Abstract | BACKGROUND: RESULTS: The four groups treated with placebo demonstrated total 30-day events of 15.9% for day 1 percutaneous coronary intervention, 17.7%, 15.0% and 18.2%, respectively, for successive intervals of later intervention. Later intervention was associated with more pre-procedural events (2.2% to 13.7%, P=0.001) which was balanced by a decrease in procedure-related events (12.1 to 3.1%, P=0.001), while the overall 30-day event rates were similar. Eptifibatide-treated patients with percutaneous coronary intervention on day 1 had the lowest rate of 30-day events (9.2%, P<0.05 vs other groups). In this group, pre-procedural risk was only 0.3%, while percutaneous coronary intervention on eptifibatide treatment was associated with low procedural risk (7.2%). The total 30-day event rate for later percutaneous coronary intervention in patients receiving eptifibatide was 14.0 on days 2 and 3, 15.0% for days 4 to 7 and 17.4% for days 7 to 30, respectively. CONCLUSION:
|
Authors | E Ronner, E Boersma, K M Akkerhuis, R A Harrington, A M Lincoff, J W Deckers, K Karsch, N S Kleiman, A Vahanian, E J Topol, R M Califf, M L Simoons |
Journal | European heart journal
(Eur Heart J)
Vol. 23
Issue 3
Pg. 239-46
(Feb 2002)
ISSN: 0195-668X [Print] England |
PMID | 11792139
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2001 The European Society of Cardiology. |
Chemical References |
- Peptides
- Placebos
- Platelet Glycoprotein GPIIb-IIIa Complex
- Platelet Glycoprotein GPIb-IX Complex
- Platelet Membrane Glycoproteins
- glycoprotein receptor GPIb-IX
- Eptifibatide
|
Topics |
- Acute Disease
- Angioplasty, Balloon, Coronary
- Combined Modality Therapy
- Coronary Disease
(complications, mortality, therapy)
- Electrocardiography
- Endpoint Determination
- Eptifibatide
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Peptides
(antagonists & inhibitors, therapeutic use)
- Placebos
- Platelet Glycoprotein GPIIb-IIIa Complex
(antagonists & inhibitors, therapeutic use)
- Platelet Glycoprotein GPIb-IX Complex
(antagonists & inhibitors, therapeutic use)
- Platelet Membrane Glycoproteins
- Postoperative Complications
(etiology, mortality)
- Survival Analysis
- Syndrome
- Time Factors
- Treatment Outcome
|